Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of GR1802 Injection in Combination With Background Therapy in Patients With SAR

NCT07154342 is registered in ClinicalTrials.gov with Genrix (Shanghai) Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07154342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07154342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of GR1802 Injection in Combination With Background Therapy in Patients With SAR
Lead sponsor
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
August 15, 2025
Completion date
July 31, 2026
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinitis, seasonal